NCT03376737

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to confirm the safety and efficacy of Apatinib plus Pemetrexed as the Maintenance Therapy in Advanced Lung Adenocarcinoma.

Detailed description

Lung adenocarcinoma is the most common NSCLC,most patient were diagnosed to advanced stage. Maintenance treatment is the continuation of treatment after first-line treatment and before the disease progresses. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients. We designed the study to explore the possibility of apatinib for maintenance.

Conditions

• Lung Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)

Timeline

• Start date: 2017-10-12
• Primary completion: 2018-06-01
• Completion: 2019-06-01
• First posted: 2017-12-18
• Last updated: 2017-12-18

Locations

1 site across 1 country: China